Cilostazol reduces MCP-1-induced chemotaxis and adhesion of THP-1 monocytes by inhibiting CCR2 gene expression

Biochemical and Biophysical Research Communications

Volumn 411, Issue 2, 2011, Pages 402-408

  Chuang, Shih Yi ^a   Yang, Su Hui ^a   Pang, Jong Hwei S ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Atherosclerosis; CCR2; Chemotaxis; Cilostazol; MCP 1; Monocytes

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CILOSTAZOL; CYCLIC AMP; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1;

ARTICLE; ATHEROSCLEROSIS; CELL ADHESION; CELL INFILTRATION; CELL MEMBRANE; CHEMOTAXIS; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MONOCYTE; PHOSPHORYLATION; PRIORITY JOURNAL;

ATHEROSCLEROSIS; CELL ADHESION; CHEMOKINE CCL2; CHEMOTAXIS; GENE EXPRESSION; HUMANS; MONOCYTES; PHOSPHODIESTERASE 3 INHIBITORS; PLATELET AGGREGATION INHIBITORS; PROTEIN BIOSYNTHESIS; RECEPTORS, CCR2; TETRAZOLES;

EID: 79960834020     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.06.163     Document Type: Article

References (31)

1. Hansson G.K. Inflammatory mechanisms in atherosclerosis. J. Thromb. Haemost. 2009, 7(Suppl. 1):328-331.
2. Amasyali B., Kose S., Kursaklioglu H., Barcin C., Kilic A. Monocyte chemoattractant protein-1 in acute coronary syndromes: complex vicious interaction. Int. J. Cardiol. 2009, 136:356-357.
3. Tieu B.C., Lee C., Sun H., Lejeune W., Recinos A., Ju X., Spratt H., Guo D.C., Milewicz D., Tilton R.G., Brasier A.R. An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice. J. Clin. Invest. 2009, 119:3637-3651.
4. Green S.R., Han K.H., Chen Y., Almazan F., Charo I.F., Miller Y.I., Quehenberger O. The CC chemokine MCP-1 stimulates surface expression of CX3CR1 and enhances the adhesion of monocytes to fractalkine/CX3CL1 via p38 MAPK. J. Immunol. 2006, 176:7412-7420.
5. Hiraoka M., Nitta N., Nagai M., Shimokado K., Yoshida M. MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway. Life Sci. 2004, 75:1333-1341.
6. Kuziel W.A., Morgan S.J., Dawson T.C., Griffin S., Smithies O., Ley K., Madea N. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor2. Proc. Natl. Acad. Sci. USA 1997, 94:12053-12058.
7. Weintraub W.S. The vascular effects of cilostazol. Can. J. Cardiol. 2006, 22(Suppl. B):56B-60B.
8. Schrör K. The pharmacology of cilostazol. Diabetes Obes Metab. 2002, 4(Suppl. 2):S9-S14.
9. Stone W.M., Demaerschalk B.M., Fowl R.J., Money S.R. Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication. J. Stroke Cerebrovasc. Dis. 2008, 17:129-133.
10. Takigawa T., Matsumaru Y., Hayakawa M., Nemoto S., Matsumura A. Cilostazol reduces restenosis after carotid artery stenting. J. Vasc. Surg. 2010, 51:51-56.
11. Dindyal S., Kyriakides C. A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy. Recent Patent Cardiovasc. Drug Discovery 2009, 4:6-14.
12. Agrawal N.K., Maiti R., Dash D., Pandey B.L. Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. Pharmacol. Res. 2007, 56:118-123.
13. Sallustio F., Rotondo F., Di Legge S., Stanzione P. Cilostazol in the management of atherosclerosis. Curr. Vasc. Pharmacol. 2010, 8:363-372.
14. Park S.Y., Lee J.H., Kim C.D., Lee W.S., Park W.S., Han J., Kwak Y.-G., Kim K.Y., Hong K.W. Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of cAMP-dependent protein kinase-mediated maxi-k channel activation. J. Pharmacol. Exp. Ther. 2006, 317:1238-1245.
15. Hattori Y., Suzuki K., Tomizawa A., Hirama N., Okayasu T., Hattori S., Satoh H., Akimoto K., Kasai K. Cilostazol inhibits cytokine-induced nuclear factor-κB activation via AMP-activated protein kinase activation in vascular endothelial cells. Cardiovasc. Res. 2009, 81:133-139.
16. Mori D., Ishii H., Kojima C., Nitta N., Nakajima K., Yoshida M. Cilostazol inhibits monocytic cell adhesion to vascular endothelium via upregulation of cAMP. J. Atheroscler. Thromb. 2007, 14:213-218.
17. Yoo A.R., Koh S.-H., Cho G.W., Kim S.H. Inhibitory effects of cilostazol on proliferation of vascular smooth muscle cells (VSMCs) through suppression of the ERK1/2 pathway. J. Atheroscler. Thromb. 2010, 17:1009-1018.
18. Hayashi S.-I., Morishita R., Matsushita H., Nakagami H., Taniyama Y., Nakamura T., Aoki M., Yamamoto K., Higaki J., Ogihara T. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells accompanied by induction of p53 and p21. Hypertension 2000, 35:237-243.
19. Okutsu R., Yoshikawa T., Nagasawa M., Hirose Y., Takase H., Mitani K., Okada K., Miyakoda G., Yabuuchi Y. Cilostazol inhibits modified low-density lipoprotein uptake and foam cell formation in mouse peritoneal macrophages. Atherosclerosis 2009, 204:405-411.
20. Rizzo M., Corrado E., Patti A.M., Rini G.B., Mikhailidis D.P. Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?. Expert Opin. Pharmacother. 2011, 12:647-655.
21. Dindyal S., Kyriakides C. A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy. Recent Pat Cardiovasc. Drug Discov. 2009, 4:6-14.
22. Noé L., Peeters K., Izzi B., Van Geet C., Freson K. Regulators of platelet cAMP levels: clinical and therapeutic implications. Curr. Med. Chem. 2010, 17:2897-2905.
23. Shemarova I.V. cAMP-dependent signal pathways in unicellular eukaryotes. Crit. Rev. Microbiol. 2009, 35:23-42.
24. Lorenowicz M.J., Fernandez-Borja M., Hordijk P.L. cAMP signaling in leukocyte transendothelial migration. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1014-1022.
25. Ni W., Kitamoto S., Ishibashi M., Usui M., Inoue S., Hiasa K., Zhao Q., Nishida K., Takeshita A., Egashira K. Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler. Thromb. Vasc. Biol. 2004, 24:534-539.
26. Han K.H., Han K.O., Green S.R., Quehenberger O. Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocyte function. J Lipid Res. 1999, 40:1053-1063.
27. Boring L., Gosling J., Cleary M., Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998, 394:894-897.
28. Ni W., Egashira K., Kitamoto S., Kataoka C., Koyanagi M., Inoue S., Imaizumi K., Akiyama C., Nishida K.-i., Takeshita A. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 2001, 103:2096-2101.
29. Inoue S., Egashira K., Ni W., Kitamoto S., Usui M., Otani K., Ishibashi M., Hiasa K.-i., Nishida K.-i., Takeshita A. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 2002, 106.
30. Kang Y.S., Lee M.H., Song H.K., Ko G.J., Kwon O.S., Lim T.K., Kim S.H., Han S.Y., Han K.H., Lee J.E., Han J.Y., Kim H.K., Cha D.R. CCR2 antagonism improves insulin resistance lipid metabolism and diabetic nephropathy in type 2 diabetic mice. Kidney Int. 2010, 78:883-894.
31. Silva A.R., Pacheco P., Vieira-de-Abreu A., Maya-Monteiro C.M., D'Alegria B., Magalhães K.G., de Assis E.F., Bandeira-Melo C., Castro-Faria-Neto H.C., Bozza P.T. Lipid bodies in oxidized LDL-induced foam cells are leukotriene-synthesizing organelles: a MCP-1/CCL2 regulated phenomenon. Biochim. Biophys. Acta 2009, 1791:1066-1075.